Prognostic Implications of the Differentiation Inhibitory Factornm23-H1 Protein in the Plasma of Aggressive Non-Hodgkin’s Lymphoma
Open Access
- 15 November 1999
- journal article
- Published by American Society of Hematology in Blood
- Vol. 94 (10) , 3541-3550
Abstract
The outcome of patients with non-Hodgkin’s lymphoma has been improved by current approaches to treatment. Nevertheless, many patients either do not have a complete remission or ultimately relapse. To identify such patients, it is important to be able to predict the outcome. We previously found that the differentiation inhibitory factor/nm23 was correlated with the prognosis of acute myeloid leukemia. To examine the prognostic effect of nm23 on non-Hodgkin’s lymphoma, we established an enzyme-linked immunosorbent assay procedure to determine nm23-H1 protein levels in plasma and assessed the association of this protein level with the response to chemotherapy, overall survival, and progression-free survival in patients with aggressive non-Hodgkin’s lymphoma. The plasma concentration of nm23-H1 was significantly higher in patients with malignant lymphoma than in normal controls, especially in aggressive non-Hodgkin’s lymphoma. The complete remission rate in patients with higher nm23-H1 levels was significantly worse than that in patients with lower nm23-H1 levels. Overall survival and progression-free survival were also lower in patients with higher nm23-H1 levels than in those with lower levels. The 3-year survival rates in patients with low and high nm23-H1levels were 79.5% and 6.7% (P = .0001). A multivariate analysis of prognostic factors showed that the plasma nm23-H1level was independently associated with the survival and progression-free survival. An elevated plasma nm23-H1concentration predicts a poor outcome of advanced non-Hodgkin’s lymphoma. Therefore, nm23-H1 in plasma may be useful for identifying a distinct group of patients at very high risk.Keywords
This publication has 36 references indexed in Scilit:
- nm23 -H4, a new member of the family of human nm23 /nucleoside diphosphate kinase genes localised on chromosome 16p13Human Genetics, 1997
- Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1995
- A new function of Nm23/NDP kinase as a differentiation inhibitory factor, which does not require it's kinase activityFEBS Letters, 1995
- Nm23/nucleoside diphosphate kinase: Toward a structural and biochemical understanding of its biological functionsBioEssays, 1995
- Autophosphorylation of nucleoside diphosphate kinase on non‐histidine residuesFEBS Letters, 1994
- The humanNME2 gene lies within 18kb ofNME1 in chromosome 17Genes, Chromosomes and Cancer, 1993
- Molecular cloning and functional expression of the second mouse nm23/NDP kinase gene, nm23‐M2FEBS Letters, 1992
- Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinaseBiochemical and Biophysical Research Communications, 1992
- Transferrin binding to K562 cell line *1Effect of heme and sodium butyrate inductionExperimental Cell Research, 1982
- National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usageCancer, 1982